Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
Become a Member | Sign in
Home>News>This Article

Eurofins Lancaster Laboratories and Celsis International Partner

Published: Tuesday, November 19, 2013
Last Updated: Tuesday, November 19, 2013
Bookmark and Share
Collaboration to provide pharmaceutical companies faster, more cost-effective rapid micro validation and screening services than traditional methods.

Eurofins Lancaster Laboratories and Celsis International Ltd. have announced that they have entered into a collaboration through which Eurofins Lancaster Laboratories will provide contract rapid microbiology validation and screening services for the Celsis rapid detection technology platform.

The Celsis rapid detection system allows companies to ensure that their products meet microbial specification 60 - 80% faster than traditional methods.

The decrease of as many as 7 to 10 days in production cycle times results in reduced inventories and working capital requirements in addition to providing earlier notification of microbial excursions when they occur.

“The pharmaceutical industry has begun to embrace the cost savings that the Celsis method can bring to their operations,“ said Judy Madden, Vice President of Corporate Development for Celsis. “We’re working with some of the pharmaceutical industry’s leaders to implement the Celsis method for microbial limits and sterility testing but many don’t have the resources or expertise to complete the validation work required before implementation. Eurofins Lancaster Laboratories’ expertise in this area will ensure high-quality validations and streamline the implementation process for our customers.”

With 50 years of delivering outstanding testing services, Eurofins Lancaster Laboratories has a stellar reputation for excellence in service quality and data reliability, enjoys long-standing relationships with many Fortune 500 clients and is part of the largest network of harmonized bio/pharmaceutical GMP product testing laboratories worldwide.

“We are pleased to have expanded our rapid technologies service offerings with the Celsis system in response to this industry need,” said Mark Kaiser, Director of Pharmaceutical Microbiology. “We have the Celsis system fully operational in both our US and Irish facilities, and both sites have initiated validation projects under contract. In addition to these, we anticipate that some of our current client base will move their routine microbiology testing to the Celsis method accelerating product release.”

Judy Madden added, “We’re excited that this collaboration will further advance the development of our pharmaceutical initiative by addressing an unmet market need.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Enzyme Malfunction May be Why Binge Drinking Can Lead to Alcoholism
A new study in mice shows that restoring the synthesis of a key brain chemical tied to inhibiting addictive behavior may help prevent alcohol cravings following binge drinking.
Cell's Waste Disposal System Regulates Body Clock Proteins
New way to identify interacting proteins could identify potential drug targets.
Compound Doubles Up On Cancer Detection
Researchers have found that tagging a pair of markers found almost exclusively on a common brain cancer yields a cancer signal that is both more obvious and more specific to cancer.
Promising Drug Candidate to Treat Chronic Itch
In a new study, scientists from the Florida campus of The Scripps Research Institute (TSRI) describe a class of compounds with the potential to stop chronic itch without the adverse side effects normally associated with medicating the condition.
Are Changes to Current Colorectal Cancer Screening Guidelines Required?
Editorial suggests more research is needed to pinpoint age to end aggressive screening.
Assessing Cancer Patient Survival and Drug Sensitivity
RNA editing events another way to investigate biomarkers and therapy targets.
New Molecular Marker for Killer Cells
Cell marker enables prognosis about the course of infections.
Potential Target for Treatment of Autism
Grant of $2.4 million will support further research.
Sniffing Out Cancer
Scientists have been exploring new ways to “smell” signs of cancer by analyzing what’s in patients’ breath.
Inroads Against Leukaemia
Potential for halting disease in molecule isolated from sea sponges.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos